90 related articles for article (PubMed ID: 17064758)
1. Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center.
Legge F; Eaton D; Molife R; Ferrandina G; Judson I; de Bono J; Kaye S
Gynecol Oncol; 2007 Mar; 104(3):551-6. PubMed ID: 17064758
[TBL] [Abstract][Full Text] [Related]
2. Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital.
Karavasilis V; Digue L; Arkenau T; Eaton D; Stapleton S; de Bono J; Judson I; Kaye S
Eur J Cancer; 2008 May; 44(7):978-82. PubMed ID: 18362066
[TBL] [Abstract][Full Text] [Related]
3. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.
Ho J; Pond GR; Newman C; Maclean M; Chen EX; Oza AM; Siu LL
BMC Cancer; 2006 Nov; 6():263. PubMed ID: 17092349
[TBL] [Abstract][Full Text] [Related]
4. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
[TBL] [Abstract][Full Text] [Related]
5. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?
Arkenau HT; Olmos D; Ang JE; Barriuso J; Karavasilis V; Ashley S; de Bono J; Judson I; Kaye S
Eur J Cancer; 2008 Jul; 44(11):1536-40. PubMed ID: 18550361
[TBL] [Abstract][Full Text] [Related]
6. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.
Vemulapalli S; Chintala L; Tsimberidou AM; Dhillon N; Lei X; Hong D; Kurzrock R
Am J Hematol; 2009 Jul; 84(7):408-13. PubMed ID: 19437507
[TBL] [Abstract][Full Text] [Related]
8. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials.
Weinfurt KP; Castel LD; Li Y; Sulmasy DP; Balshem AM; Benson AB; Burnett CB; Gaskin DJ; Marshall JL; Slater EF; Schulman KA; Meropol NJ
Cancer; 2003 Jul; 98(1):166-75. PubMed ID: 12833469
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.
Arkenau HT; Brunetto AT; Barriuso J; Olmos D; Eaton D; de Bono J; Judson I; Kaye S
Oncology; 2009; 76(3):151-6. PubMed ID: 19169046
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial accrual among new cancer patients at a community-based cancer center.
Go RS; Frisby KA; Lee JA; Mathiason MA; Meyer CM; Ostern JL; Walther SM; Schroeder JE; Meyer LA; Umberger KE
Cancer; 2006 Jan; 106(2):426-33. PubMed ID: 16353206
[TBL] [Abstract][Full Text] [Related]
11. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
Hlubocky FJ; Ratain MJ; Wen M; Daugherty CK
J Clin Oncol; 2007 Feb; 25(5):548-54. PubMed ID: 17290064
[TBL] [Abstract][Full Text] [Related]
12. Willingness of gynecologic cancer patients to participate in clinical trials.
Mathews C; Restivo A; Raker C; Weitzen S; Disilvestro P
Gynecol Oncol; 2009 Jan; 112(1):161-5. PubMed ID: 18952272
[TBL] [Abstract][Full Text] [Related]
13. Length of survival in hospice for cancer patients referred from a comprehensive cancer center.
Younis T; Milch R; Abul-Khoudoud N; Lawrence D; Mirand A; Levine E
Am J Hosp Palliat Care; 2009; 26(4):281-7. PubMed ID: 19357376
[TBL] [Abstract][Full Text] [Related]
14. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials.
Lemieux J; Goodwin PJ; Pritchard KI; Gelmon KA; Bordeleau LJ; Duchesne T; Camden S; Speers CH
J Clin Oncol; 2008 Sep; 26(27):4458-65. PubMed ID: 18802158
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of women with gynecologic cancer who enter clinical trials.
Luck MB; McIntire M; Blades N; Robinson W
J Reprod Med; 2005 Jul; 50(7):481-5. PubMed ID: 16130843
[TBL] [Abstract][Full Text] [Related]
16. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis.
Trivanović D; Petkovic M; Stimac D
Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):43-8. PubMed ID: 18976894
[TBL] [Abstract][Full Text] [Related]
17. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
[TBL] [Abstract][Full Text] [Related]
18. External validity of ST elevation myocardial infarction trials: the Zwolle studies.
Rasoul S; Ottervanger JP; Dambrink JH; Boer MJ; Hoorntje JC; Gosselink AT; Zijlstra F; Suryapranata H; van 't Hof AW
Catheter Cardiovasc Interv; 2007 Apr; 69(5):632-6. PubMed ID: 17253599
[TBL] [Abstract][Full Text] [Related]
19. Factors that influence the recruitment of patients to Phase III studies in oncology: the perspective of the clinical research associate.
Wright JR; Crooks D; Ellis PM; Mings D; Whelan TJ
Cancer; 2002 Oct; 95(7):1584-91. PubMed ID: 12237929
[TBL] [Abstract][Full Text] [Related]
20. The impact of consenter characteristics and experience on patient interest in clinical research.
Rasco DW; Xie Y; Yan J; Sayne JR; Skinner CS; Dowell JE; Gerber DE
Oncologist; 2009 May; 14(5):468-75. PubMed ID: 19401521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
